Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a strong-buy rating in a report published on Thursday morning.

Separately, Cantor Fitzgerald restated a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $30.76 on Thursday. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of 28.75 and a beta of 0.90. The firm has a 50-day moving average of $32.76 and a two-hundred day moving average of $35.03. Supernus Pharmaceuticals has a 1 year low of $25.53 and a 1 year high of $40.28.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Jonathan Rubin sold 927 shares of the firm’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares of the company’s stock, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,104 shares of company stock valued at $440,263. Company insiders own 9.30% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Vident Advisory LLC raised its stake in shares of Supernus Pharmaceuticals by 2.2% during the 4th quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock worth $520,000 after acquiring an additional 309 shares in the last quarter. Summit Investment Advisors Inc. grew its holdings in Supernus Pharmaceuticals by 7.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock worth $190,000 after purchasing an additional 369 shares during the last quarter. Bank of Montreal Can increased its position in shares of Supernus Pharmaceuticals by 6.6% during the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock worth $275,000 after purchasing an additional 473 shares in the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Supernus Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock valued at $800,000 after purchasing an additional 560 shares during the last quarter. Finally, HighTower Advisors LLC lifted its holdings in shares of Supernus Pharmaceuticals by 7.3% during the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company’s stock valued at $330,000 after purchasing an additional 624 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.